|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STYXL1 |
Gene summary for STYXL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STYXL1 | Gene ID | 51657 |
| Gene name | serine/threonine/tyrosine interacting like 1 | |
| Gene Alias | DUSP24 | |
| Cytomap | 7q11.23 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024R4L1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51657 | STYXL1 | LZE4T | Human | Esophagus | ESCC | 1.55e-03 | 8.73e-02 | 0.0811 |
| 51657 | STYXL1 | LZE7T | Human | Esophagus | ESCC | 4.56e-05 | 2.47e-01 | 0.0667 |
| 51657 | STYXL1 | LZE20T | Human | Esophagus | ESCC | 2.65e-11 | 3.82e-01 | 0.0662 |
| 51657 | STYXL1 | LZE22D1 | Human | Esophagus | HGIN | 7.88e-03 | 2.01e-01 | 0.0595 |
| 51657 | STYXL1 | LZE22T | Human | Esophagus | ESCC | 2.27e-04 | 3.35e-01 | 0.068 |
| 51657 | STYXL1 | LZE24T | Human | Esophagus | ESCC | 4.46e-12 | 4.07e-01 | 0.0596 |
| 51657 | STYXL1 | LZE21T | Human | Esophagus | ESCC | 1.75e-06 | 2.90e-01 | 0.0655 |
| 51657 | STYXL1 | LZE6T | Human | Esophagus | ESCC | 5.71e-11 | 3.42e-01 | 0.0845 |
| 51657 | STYXL1 | P1T-E | Human | Esophagus | ESCC | 1.75e-07 | 3.11e-01 | 0.0875 |
| 51657 | STYXL1 | P2T-E | Human | Esophagus | ESCC | 4.71e-15 | 3.15e-01 | 0.1177 |
| 51657 | STYXL1 | P4T-E | Human | Esophagus | ESCC | 1.53e-36 | 7.27e-01 | 0.1323 |
| 51657 | STYXL1 | P5T-E | Human | Esophagus | ESCC | 1.73e-10 | 3.05e-01 | 0.1327 |
| 51657 | STYXL1 | P8T-E | Human | Esophagus | ESCC | 5.99e-12 | 3.22e-01 | 0.0889 |
| 51657 | STYXL1 | P9T-E | Human | Esophagus | ESCC | 1.07e-10 | 3.02e-01 | 0.1131 |
| 51657 | STYXL1 | P10T-E | Human | Esophagus | ESCC | 1.31e-16 | 3.53e-01 | 0.116 |
| 51657 | STYXL1 | P11T-E | Human | Esophagus | ESCC | 6.45e-09 | 2.12e-01 | 0.1426 |
| 51657 | STYXL1 | P12T-E | Human | Esophagus | ESCC | 1.77e-25 | 5.32e-01 | 0.1122 |
| 51657 | STYXL1 | P15T-E | Human | Esophagus | ESCC | 3.49e-28 | 5.79e-01 | 0.1149 |
| 51657 | STYXL1 | P16T-E | Human | Esophagus | ESCC | 6.58e-84 | 1.48e+00 | 0.1153 |
| 51657 | STYXL1 | P17T-E | Human | Esophagus | ESCC | 1.11e-12 | 3.88e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:009719327 | Esophagus | HGIN | intrinsic apoptotic signaling pathway | 90/2587 | 288/18723 | 1.50e-14 | 2.80e-12 | 90 |
| GO:200124227 | Esophagus | HGIN | regulation of intrinsic apoptotic signaling pathway | 58/2587 | 164/18723 | 2.57e-12 | 3.58e-10 | 58 |
| GO:200123327 | Esophagus | HGIN | regulation of apoptotic signaling pathway | 97/2587 | 356/18723 | 1.36e-11 | 1.57e-09 | 97 |
| GO:200124410 | Esophagus | HGIN | positive regulation of intrinsic apoptotic signaling pathway | 25/2587 | 58/18723 | 4.91e-08 | 2.75e-06 | 25 |
| GO:200123519 | Esophagus | HGIN | positive regulation of apoptotic signaling pathway | 41/2587 | 126/18723 | 6.06e-08 | 3.22e-06 | 41 |
| GO:001063920 | Esophagus | HGIN | negative regulation of organelle organization | 79/2587 | 348/18723 | 4.12e-06 | 1.37e-04 | 79 |
| GO:19021156 | Esophagus | HGIN | regulation of organelle assembly | 46/2587 | 186/18723 | 4.63e-05 | 1.12e-03 | 46 |
| GO:004593626 | Esophagus | HGIN | negative regulation of phosphate metabolic process | 89/2587 | 441/18723 | 1.24e-04 | 2.54e-03 | 89 |
| GO:001056326 | Esophagus | HGIN | negative regulation of phosphorus metabolic process | 89/2587 | 442/18723 | 1.34e-04 | 2.71e-03 | 89 |
| GO:000647017 | Esophagus | HGIN | protein dephosphorylation | 61/2587 | 281/18723 | 1.86e-04 | 3.51e-03 | 61 |
| GO:003530425 | Esophagus | HGIN | regulation of protein dephosphorylation | 24/2587 | 90/18723 | 9.27e-04 | 1.17e-02 | 24 |
| GO:00340638 | Esophagus | HGIN | stress granule assembly | 10/2587 | 26/18723 | 1.60e-03 | 1.79e-02 | 10 |
| GO:19021162 | Esophagus | HGIN | negative regulation of organelle assembly | 13/2587 | 41/18723 | 2.62e-03 | 2.58e-02 | 13 |
| GO:005134620 | Esophagus | HGIN | negative regulation of hydrolase activity | 72/2587 | 379/18723 | 2.81e-03 | 2.75e-02 | 72 |
| GO:004366619 | Esophagus | HGIN | regulation of phosphoprotein phosphatase activity | 16/2587 | 58/18723 | 4.35e-03 | 3.84e-02 | 16 |
| GO:003530320 | Esophagus | HGIN | regulation of dephosphorylation | 29/2587 | 128/18723 | 4.41e-03 | 3.87e-02 | 29 |
| GO:0097193111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway | 222/8552 | 288/18723 | 5.87e-28 | 2.02e-25 | 222 |
| GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
| GO:2001242111 | Esophagus | ESCC | regulation of intrinsic apoptotic signaling pathway | 128/8552 | 164/18723 | 1.75e-17 | 1.50e-15 | 128 |
| GO:0010563111 | Esophagus | ESCC | negative regulation of phosphorus metabolic process | 274/8552 | 442/18723 | 2.32e-12 | 9.41e-11 | 274 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STYXL1 | SNV | Missense_Mutation | c.555N>C | p.Leu185Phe | p.L185F | Q9Y6J8 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| STYXL1 | insertion | In_Frame_Ins | novel | c.607_608insTGG | p.Ala202_Gly203insVal | p.A202_G203insV | Q9Y6J8 | protein_coding | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| STYXL1 | insertion | In_Frame_Ins | novel | c.605_606insCCACCAGTTACTTAACTCATCAAG | p.Ala202_Gly203insHisGlnLeuLeuAsnSerSerArg | p.A202_G203insHQLLNSSR | Q9Y6J8 | protein_coding | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| STYXL1 | SNV | Missense_Mutation | c.932C>T | p.Pro311Leu | p.P311L | Q9Y6J8 | protein_coding | tolerated(0.13) | benign(0.204) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| STYXL1 | SNV | Missense_Mutation | c.679N>A | p.His227Asn | p.H227N | Q9Y6J8 | protein_coding | tolerated(0.35) | benign(0.158) | TCGA-EA-A43B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| STYXL1 | SNV | Missense_Mutation | rs372639771 | c.469C>G | p.Gln157Glu | p.Q157E | Q9Y6J8 | protein_coding | tolerated(0.15) | benign(0.003) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| STYXL1 | SNV | Missense_Mutation | c.555N>C | p.Leu185Phe | p.L185F | Q9Y6J8 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| STYXL1 | SNV | Missense_Mutation | c.191N>T | p.Glu64Val | p.E64V | Q9Y6J8 | protein_coding | tolerated(0.09) | benign(0.245) | TCGA-AA-3818-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| STYXL1 | SNV | Missense_Mutation | novel | c.739N>G | p.Thr247Ala | p.T247A | Q9Y6J8 | protein_coding | tolerated(0.08) | possibly_damaging(0.542) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| STYXL1 | SNV | Missense_Mutation | c.514N>G | p.Asn172Asp | p.N172D | Q9Y6J8 | protein_coding | tolerated(0.35) | benign(0.02) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |